EGFR and non-small cell lung carcinoma: Considering the controversies regarding the use of first‐line osimertinib followed by other therapies or first‐line first‐/second‐generation TKIs followed by osimertinib as appropriate options for treating EGFR‐mutated NSCLC patients,15 the RWD from RESET might be of interest.